{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:24:54Z","timestamp":1772166294910,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7192057"],"award-info":[{"award-number":["7192057"]}]},{"name":"Capital Health Development Research Project","award":["2020-2-1072"],"award-info":[{"award-number":["2020-2-1072"]}]},{"name":"Beijing Hospitals Authority Youth Programme","award":["QML20190506"],"award-info":[{"award-number":["QML20190506"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Patients with low-grade gliomas (LGGs) harboring\n O<\/jats:italic>\n \n 6<\/jats:italic>\n <\/jats:sup>\n -methylguanine-DNA methyltransferase<\/jats:italic>\n promoter nonmethylation (\n MGMT<\/jats:italic>\n -non-pM) have a particularly short survival and are great resistance to chemotherapy. The objective of this study was to assess the efficacy of high-dose radiotherapy (RT) for LGGs with\n MGMT<\/jats:italic>\n -non-pM.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n 268 patients with newly diagnosed adult supratentorial LGGs from the multicenter Chinese Glioma Cooperative Group (CGCG) received postoperative RT during 2005\u20132018.\n MGMT<\/jats:italic>\n promoter methylation analysis was conducted by pyrosequencing in all patients. Univariate and multivariate analysis were performed using the Cox regression to determine the prognostic factors for overall survival (OS) and progression-free survival (PFS). RT dose\u2013response on\n MGMT<\/jats:italic>\n status defined subtypes was analyzed.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n On univariate analysis, the following were statistically significant favorable factors for both PFS and OS: oligodendrogliomas(\n p<\/jats:italic>\n \u2009=\u20090.002 and\n p<\/jats:italic>\n \u2009=\u20090.005), high-dose RT (>\u200954\u00a0Gy) (\n p<\/jats:italic>\n \u2009=\u20090.021 and\n p<\/jats:italic>\n \u2009=\u20090.029) and 1p\/19q codeletion (\n p<\/jats:italic>\n \u2009<\u20090.001 and\n p<\/jats:italic>\n \u2009=\u20090.001). On multivariate analysis, RT dose (>\u200954\u00a0Gy\n vs.<\/jats:italic>\n \u2009\u2264\u200954\u00a0Gy) and\n IDH<\/jats:italic>\n mutation were independently prognostic markers for OS (HR, 0.47; 95%CI, 0.22\u20130.98;\n p<\/jats:italic>\n \u2009=\u20090.045; and HR, 0.44; 95%CI, 0.21\u20130.96;\n p<\/jats:italic>\n \u2009=\u20090.038, respectively) and PFS (HR, 0.48; 95%CI, 0.26\u20130.90;\n p<\/jats:italic>\n \u2009=\u20090.022; and HR, 0.51; 95%CI, 0.26\u20130.98;\n p<\/jats:italic>\n \u2009=\u20090.044, respectively). High-dose RT was associated with longer OS (HR, 0.56; 95%CI, 0.32\u20130.96;\n p<\/jats:italic>\n \u2009=\u20090.036) and PFS (HR, 0.58; 95%CI, 0.35\u20130.96;\n p<\/jats:italic>\n \u2009=\u20090.033) than low-dose RT in\n MGMT<\/jats:italic>\n -non-pM subtype. In contrast, no significant difference in either OS (\n p<\/jats:italic>\n \u2009=\u20090.240) or PFS (\n p<\/jats:italic>\n \u2009=\u20090.395) was observed with high-dose RT in the\n MGMT<\/jats:italic>\n -pM subtype.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n High-dose RT (>\u200954\u00a0Gy) is an independently protective factor for LGGs and is associated with improved survival in patients with\n MGMT-<\/jats:italic>\n non-pM.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s13014-021-01878-3","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T03:05:09Z","timestamp":1629342309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase"],"prefix":"10.1186","volume":"16","author":[{"given":"Yanwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-9827","authenticated-orcid":false,"given":"Xiaoguang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"1878_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.canlet.2020.10.050","volume":"499","author":"T Jiang","year":"2021","unstructured":"Jiang T, Nam DH, Ram Z, et al. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2021;499:60\u201372.","journal-title":"Cancer Lett"},{"key":"1878_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017. Neuro Oncol. 2020;22:iv1\u201396.","journal-title":"Neuro Oncol"},{"key":"1878_CR3","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell EH, Zhang P, Shaw EG, et al. Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol. 2020;38:3407\u201317.","journal-title":"J Clin Oncol"},{"key":"1878_CR4","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.08.025","volume":"105","author":"MC Tom","year":"2019","unstructured":"Tom MC, Park DYJ, Yang K, et al. Malignant transformation of molecularly classified adult low-grade glioma. Int J Radiat Oncol Biol Phys. 2019;105:1106\u201312.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1878_CR5","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/neuonc\/not117","volume":"15","author":"T Gorlia","year":"2013","unstructured":"Gorlia T, Wu W, Wang M, et al. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC\/RTOG\/NCCTG phase III clinical trials. Neuro Oncol. 2013;15:1568\u201379.","journal-title":"Neuro Oncol"},{"key":"1878_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","volume":"366","author":"MJ van den Bent","year":"2005","unstructured":"van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985\u201390.","journal-title":"Lancet"},{"key":"1878_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3171\/JNS\/2008\/109\/11\/0835","volume":"109","author":"EG Shaw","year":"2008","unstructured":"Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109:835\u201341.","journal-title":"J Neurosurg"},{"key":"1878_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803\u201320.","journal-title":"Acta Neuropathol"},{"key":"1878_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/ana.21044","volume":"60","author":"S Everhard","year":"2006","unstructured":"Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol. 2006;60:740\u20133.","journal-title":"Ann Neurol"},{"key":"1878_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1227\/NEU.0b013e3181f743f5","volume":"67","author":"P Jha","year":"2010","unstructured":"Jha P, Suri V, Jain A, et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery. 2010;67:1681\u201391.","journal-title":"Neurosurgery"},{"key":"1878_CR11","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/jamaoncol.2018.1977","volume":"4","author":"EH Bell","year":"2018","unstructured":"Bell EH, Zhang P, Fisher BJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology\/RTOG 0424 trial. JAMA Oncol. 2018;4:1405\u20139.","journal-title":"JAMA Oncol"},{"key":"1878_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003.","journal-title":"N Engl J Med"},{"key":"1878_CR13","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2015.63.4691","volume":"34","author":"U Herrlinger","year":"2016","unstructured":"Herrlinger U, Schafer N, Steinbach JP, et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol. 2016;34:1611\u20139.","journal-title":"J Clin Oncol"},{"key":"1878_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11060-016-2094-0","volume":"128","author":"M Khasraw","year":"2016","unstructured":"Khasraw M, Lee A, McCowatt S, et al. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. J Neurooncol. 2016;128:163\u201371.","journal-title":"J Neurooncol"},{"key":"1878_CR15","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","volume":"22","author":"W Wick","year":"2016","unstructured":"Wick W, Gorlia T, Bady P, et al. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin Cancer Res. 2016;22:4797\u2013806.","journal-title":"Clin Cancer Res"},{"key":"1878_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/COC.0000000000000247","volume":"41","author":"H Elinzano","year":"2018","unstructured":"Elinzano H, Glantz M, Mrugala M, et al. PPX and concurrent radiation for newly diagnosed glioblastoma without MGMT methylation: a randomized phase II study: BrUOG 244. Am J Clin Oncol. 2018;41:159\u201362.","journal-title":"Am J Clin Oncol"},{"key":"1878_CR17","doi-asserted-by":"publisher","first-page":"9461402","DOI":"10.1155\/2017\/9461402","volume":"2017","author":"P Tini","year":"2017","unstructured":"Tini P, Nardone V, Pastina P, et al. Patients affected by unmethylated O(6)-methylguanine-DNA methyltransferase glioblastoma undergoing radiochemotherapy may benefit from moderately dose-escalated radiotherapy. Biomed Res Int. 2017;2017:9461402.","journal-title":"Biomed Res Int"},{"key":"1878_CR18","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","volume":"18","author":"LB Nabors","year":"2020","unstructured":"Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020;18:1537\u201370.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1878_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","volume":"13","author":"W Wick","year":"2012","unstructured":"Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707\u201315.","journal-title":"Lancet Oncol"},{"key":"1878_CR20","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstrom","year":"2012","unstructured":"Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916\u201326.","journal-title":"Lancet Oncol"},{"key":"1878_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nop020","volume":"12","author":"AL Rivera","year":"2010","unstructured":"Rivera AL, Pelloski CE, Gilbert MR, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12:116\u201321.","journal-title":"Neuro Oncol"},{"key":"1878_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/0360-3016(88)90115-0","volume":"15","author":"CA Medbery 3rd","year":"1988","unstructured":"Medbery CA 3rd, Straus KL, Steinberg SM, et al. Low-grade astrocytomas: treatment results and prognostic variables. Int J Radiat Oncol Biol Phys. 1988;15:837\u201341.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1878_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3171\/jns.1989.70.6.0853","volume":"70","author":"EG Shaw","year":"1989","unstructured":"Shaw EG, Daumas-Duport C, Scheithauer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg. 1989;70:853\u201361.","journal-title":"J Neurosurg"},{"key":"1878_CR24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/0360-3016(90)90397-3","volume":"18","author":"AC Whitton","year":"1990","unstructured":"Whitton AC, Bloom HJ. Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys. 1990;18:783\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1878_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/neuonc\/noaa021","volume":"22","author":"WG Breen","year":"2020","unstructured":"Breen WG, Anderson SK, Carrero XW, et al. Final report from Intergroup NCCTG 86\u201372-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma. Neuro Oncol. 2020;22:830\u20137.","journal-title":"Neuro Oncol"},{"key":"1878_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0360-3016(96)00352-5","volume":"36","author":"AB Karim","year":"1996","unstructured":"Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549\u201356.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1878_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/COC.0b013e318271ae03","volume":"37","author":"AK Paulsson","year":"2014","unstructured":"Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol. 2014;37:177\u201381.","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"1878_CR28","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/S0959-8049(98)00268-8","volume":"34","author":"GM Kiebert","year":"1998","unstructured":"Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34(12):1902\u20139.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1878_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","volume":"8","author":"L Douw","year":"2009","unstructured":"Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810\u20138.","journal-title":"Lancet Neurol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01878-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-021-01878-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01878-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T03:05:46Z","timestamp":1629342346000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01878-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1878"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01878-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-480178\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"assertion":[{"value":"30 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Institutional Review Board of Beijing Tiantan Hospital (Grant Number: KY2013-017\u201301). Informed written consent from patients was waived by the Institutional Review Board of Beijing Tiantan Hospital due to the retrospective study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}